Drugs giant AstraZeneca has admitted that the formulation patent protecting its Seroquel XR product was deemed invalid by the High Court in the UK.
The patent was challenged by Accord Healthcare, Intas Pharmaceuticals, Hexal AG and Sandoz, Teva UK, and Teva Pharmaceutical Industries.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
AstraZeneca said it is "disappointed" with the court's decision and added that the company remains committed to defending its intellectual property protecting Seroquel XR.
Shares were down 0.26% to 2,844.00p.
NR
-
Tesla seeks approval to supply electricity to UK homes – could it disrupt the energy market?Tesla has applied for a license to supply UK households with electricity, but taking on the biggest providers could prove challenging
-
Most Brits unaware onshore bonds can help beat inheritance tax – here’s howA little-known perk of certain types of bonds can let your loved ones off the hook when it comes to inheritance tax – but two-thirds of people have never heard of them
